{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:02:44Z","timestamp":1784872964064,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombotic events and\/or obstetric complications due to persistent antiphospholipid antibodies. Type I interferon (IFN) upregulation has been identified as a potential contributor to the pathophysiology of APS, however, the relationship between type I IFN and clinical manifestations of APS still needs to be delineated. The objective of this study was the evaluation of the potential role of type I IFN regarding different APS manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of APS patients who presented to our clinic between 2017 and 2024, focusing on clinical manifestations, recurring events and serological profiles in relation to Siglec-1 expression on monocytes, as a surrogate marker of type I IFN signature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of the 218 APS patients included in the study, 123 were diagnosed with primary APS (pAPS) and 95 with secondary APS (sAPS), the latter mostly SLE associated, showing a general higher type I IFN signature as the pAPS cohort. While no significant differences in Siglec-1 expression were observed across most APS manifestations (venous, arterial, mixed and obstetric events), significantly higher type I IFN activity was detected in APS patients with thrombocytopenia compared to those without (p = 0.0061). Moreover, we found an inverse correlation between platelet numbers and Siglec-1 values. Interestingly, the difference in type I IFN signature was confirmed in the pAPS cohort with thrombocytopenia (p = 0.0242). In sAPS, Siglec-1 expression did not differ significantly between patients with and without thrombocytopenia (p = 0.4664). With regard to serological and clinical characteristics, patients with thrombocytopenia exhibited a higher prevalence of triple positivity, elevated levels of anti-cardiolipin IgG antibodies and an increased incidence of recurrent and mixed (arterial\/venous) thromboembolic events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To conclude, the data indicate that type I IFN may be a relevant factor for the occurrence of thrombocytopenia in pAPS. Moreover, thrombocytopenia in APS was linked to increased prevalence of triple positivity, higher anti-cardiolipin IgG titres, and higher disease severity, underscoring the importance of closer monitoring in this subgroup. These results warrant validation in prospective studies and could support potential therapeutic targeting of type I IFN in a subset of APS patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1863789","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:35:12Z","timestamp":1784871312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced type I interferon signature in primary APS patients is associated with thrombocytopenia"],"prefix":"10.3389","volume":"17","author":[{"given":"Sophie","family":"Scholz","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Nitschke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a-Sophie","family":"Dreveton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beniam","family":"Assefa","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]},{"name":"Department of Nephrology and Intensive Medical Care, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Pru\u00df","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Luisa","family":"Stefanski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9- Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Deutsches Rheumaforschungszentrum (DRFZ)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00759-6","article-title":"Antiphospholipid syndrome","volume":"74","author":"Specker","year":"2015","journal-title":"Z Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002534","article-title":"Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study","volume":"9","author":"Laurent","year":"2023","journal-title":"RMD Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224609","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/nejmra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"379","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221088576","article-title":"The pathophysiology of the antiphospholipid syndrome: a perspective from the blood coagulation system","volume":"28","author":"Arreola-Diaz","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1585953","article-title":"Phosphatidylcholine-specific B cells are enriched among atypical CD11c(high) and CD21(low) memory B cells in antiphospholipid syndrome","volume":"16","author":"Nitschke","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: pathogenetic, clinical and therapeutic implications","volume":"104","author":"Xourgia","year":"2019","journal-title":"J Autoimmun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/138920112802273290","article-title":"Primary Sjogren's syndrome and the type I interferon system","volume":"13","author":"Nordmark","year":"2012","journal-title":"Curr Pharm Bio\/Technol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283585731","article-title":"Update: biomarkers for idiopathic inflammatory myopathies","volume":"24","author":"Nasr","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00487","article-title":"Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations","volume":"10","author":"Palli","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23404","article-title":"Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus","volume":"58","author":"Biesen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1182\/blood.v114.22.4187.4187","article-title":"PAKTM-lx: A new luminex*\u00ae-based assay to detect and identify antibodies to human platelet antigens (HPA) in patient serum","volume":"114","author":"Vipul Rathore","year":"2009","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23584","article-title":"The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository","volume":"71","author":"Unlu","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.3.194","article-title":"Thrombocytopenia in the antiphospholipid syndrome","volume":"56","author":"Cuadrado","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0494-8","article-title":"The significance and management of thrombocytopenia in antiphospholipid syndrome","volume":"17","author":"Artim-Esen","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02065.x","article-title":"Blood platelets activate the classical pathway of human complement","volume":"4","author":"Peerschke","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-0916","article-title":"Platelets express functional Toll-like receptor-4","volume":"106","author":"Andonegui","year":"2005","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825892","article-title":"Platelets as key factors in inflammation: focus on CD40L\/CD40","volume":"13","author":"Cognasse","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.118","article-title":"Platelets: active players in the pathogenesis of arthritis and SLE","volume":"8","author":"Boilard","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040877","article-title":"Thrombocytopenia in virus infections","volume":"10","author":"Raadsen","year":"2021","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(96)80304-7","article-title":"Immune thrombocytopenia and alpha-interferon therapy","volume":"25","author":"Dourakis","year":"1996","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-125906","article-title":"Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes","volume":"112","author":"Yamane","year":"2008","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i11.1414","article-title":"Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature","volume":"16","author":"Li","year":"2010","journal-title":"World J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"193ra89","DOI":"10.1126\/scitranslmed.3006277","article-title":"Plasmacytoid dendritic cells, interferon signaling, and FcgammaR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia","volume":"5","author":"Sehgal","year":"2013","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.957201","article-title":"Circulating immune-complexes of IgG\/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome","volume":"13","author":"Naranjo","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091170","article-title":"Immune thrombocytopenia in antiphospholipid syndrome: is it primary or secondary","volume":"9","author":"Tomasello","year":"2021","journal-title":"Biomedicines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.10.011","article-title":"Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia","volume":"84","author":"Moulinet","year":"2021","journal-title":"Eur J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103417","article-title":"Thrombocytopenia in antiphospholipid syndrome: is anticoagulation and\/or antiaggregation always required","volume":"23","author":"Zuily","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1055\/a-2510-6147","article-title":"Association of specific antiphospholipid antibodies to platelet count and thrombocytopenia","volume":"125","author":"Griem","year":"2025","journal-title":"Thromb Haemost"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.2017.71s1-po4123","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1863789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:35:12Z","timestamp":1784871312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1863789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1863789"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1863789","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1863789"}}